Loading...
Loading...
Browse all stories on DeepNewz
VisitSenate's decision on the Biosecure Act following House approval
Pass with amendments • 34%
Pass as is • 33%
Fail to pass • 33%
Senate voting records and public statements
House Committee Advances Biosecure Act (HR7085) with 40-1 Vote Targeting Chinese Biotech Suppliers
May 16, 2024, 09:15 AM
The House committee has voted 40-1 to advance the Biosecure Act, which targets Chinese biotech suppliers. The legislation, known as the Biosecure Act (HR7085), aims to restrict US companies from contracting with Chinese biotech providers, including WuXi AppTec, starting from January 31, 2032. This move is part of a broader effort by the United States to reduce China's influence in the biotech supply chain. The bill's progress is being closely watched by the biotech research community, as it could have far-reaching implications across both academia and industry. Big drugmakers are already preparing for the upcoming changes. Stocks mentioned in relation to this development include $XBI and $EVO.
View original story
Passes with majority • 33%
Fails to pass • 33%
No vote held • 33%
Passes with strong majority • 33%
Passes with weak majority • 33%
Does not pass • 34%
Pass by simple majority • 33%
Pass by two-thirds majority • 33%
Fail to pass • 33%
Passes with 60+ votes • 33%
Fails with 50-59 votes • 33%
Fails with less than 50 votes • 33%
Passes with significant majority • 33%
Passes with narrow majority • 34%
Fails to pass • 33%
Passes with majority • 33%
Fails to pass • 33%
No vote held • 33%
Passed by large majority • 33%
Passed by narrow margin • 34%
Did not pass • 33%
Passes with strong majority • 33%
Passes with narrow majority • 33%
Fails to pass • 34%
No amendments proposed • 25%
Amendments proposed, none passed • 25%
At least one amendment passed • 25%
Bill fundamentally changed by amendments • 25%
Passed by large margin • 33%
Passed by narrow margin • 33%
Rejected • 34%
Passed unanimously • 25%
Passed with opposition • 25%
Rejected • 25%
Stalled or no vote • 25%
Seek exemptions • 33%
Reformulate supply chains • 33%
Challenge the Act legally • 34%